TriangleHEALTH PROFESSIONAL · SOURCE READING
Pegylated liposomal doxorubicin (PLD)
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
PLD has shown activity in several case series and single-institution analyses.[5-8]
Evidence (PLD):
A multicenter trial included 55 patients with classic KS who were treated over a decade.[5]
Source links and citations
A multicenter trial included 55 patients with classic KS who were treated over a decade.[5]
A 71% overall response rate was seen using PLD, with a median response duration of 25 months.[5][Level of evidence C3]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice